1,830 Shares in argenex SE $ARGX Acquired by Sanders Morris Harris LLC

Sanders Morris Harris LLC acquired a new stake in argenex SE (NASDAQ:ARGX) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 1,830 shares of the company’s stock, valued at approximately $1,350,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Millennium Management LLC raised its position in shares of argenex by 316.9% in the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after buying an additional 204,180 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its stake in argenex by 114.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after acquiring an additional 158,476 shares in the last quarter. Franklin Resources Inc. grew its stake in argenex by 103.9% during the 2nd quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock valued at $154,233,000 after acquiring an additional 142,606 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in argenex by 1,203.4% in the 1st quarter. BNP Paribas Financial Markets now owns 133,359 shares of the company’s stock valued at $78,931,000 after acquiring an additional 123,127 shares during the last quarter. Finally, Braidwell LP lifted its stake in argenex by 99.2% in the 1st quarter. Braidwell LP now owns 160,849 shares of the company’s stock worth $95,201,000 after purchasing an additional 80,083 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Up 0.1%

Shares of argenex stock opened at $851.42 on Wednesday. The firm has a market cap of $52.42 billion, a PE ratio of 36.56, a price-to-earnings-growth ratio of 0.86 and a beta of 0.37. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62. The business’s fifty day simple moving average is $865.62 and its 200-day simple moving average is $722.06.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. As a group, equities analysts expect that argenex SE will post 3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Morgan Stanley boosted their target price on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. HC Wainwright upped their target price on argenex from $774.00 to $915.00 and gave the company a “buy” rating in a report on Friday, October 31st. Wedbush lifted their price target on argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a report on Friday, November 14th. Bank of America boosted their price target on shares of argenex from $880.00 to $887.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Finally, TD Cowen raised their price objective on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average price target of $968.83.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.